These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25251308)

  • 41. 23-year-old woman being treated for opioid dependence, unexpected weight gain.
    Chudgar NP; Greenblatt L
    J Fam Pract; 2014 Jul; 63(7):366-7. PubMed ID: 25198209
    [No Abstract]   [Full Text] [Related]  

  • 42. A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.
    Modak T; Sarkar S; Balhara YPS
    J Opioid Manag; 2021; 17(7):141-152. PubMed ID: 34520035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient.
    Book SW; Myrick H; Malcolm R; Strain EC
    Am J Psychiatry; 2007 Jun; 164(6):979. PubMed ID: 17541066
    [No Abstract]   [Full Text] [Related]  

  • 44. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
    Doernberg M; Krawczyk N; Agus D; Fingerhood M
    Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Buprenorphine-naloxone maintenance following release from jail.
    Lee JD; Grossman E; Truncali A; Rotrosen J; Rosenblum A; Magura S; Gourevitch MN
    Subst Abus; 2012; 33(1):40-7. PubMed ID: 22263712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 47. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible.
    Carroll JJ; Rich JD; Green TC
    J Addict Med; 2018; 12(6):459-465. PubMed ID: 30095563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.
    Griffin ML; Dodd DR; Potter JS; Rice LS; Dickinson W; Sparenborg S; Weiss RD
    Am J Drug Alcohol Abuse; 2014 Mar; 40(2):157-62. PubMed ID: 24219166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Foreword to: buprenorphine and buprenorphine/naloxone: a guide for clinicians.
    Fudala PJ; Bridge TP
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S1-2. PubMed ID: 12738345
    [No Abstract]   [Full Text] [Related]  

  • 52. Buprenorphine Prescribing: To Expand or Not to Expand.
    Li X; Shorter D; Kosten TR
    J Psychiatr Pract; 2016 May; 22(3):183-92. PubMed ID: 27123798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice".
    Woody G; Bruce D; Korthuis PT; Chhatre S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Poole S; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142-3. PubMed ID: 25243431
    [No Abstract]   [Full Text] [Related]  

  • 55. Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury.
    Kosten TR; Graham DP; Nielsen DA
    JAMA Psychiatry; 2018 Jun; 75(6):649-650. PubMed ID: 29710138
    [No Abstract]   [Full Text] [Related]  

  • 56. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acceptability of the use of cellular telephone and computer pictures/video for "pill counts" in buprenorphine maintenance treatment.
    Welsh C
    J Opioid Manag; 2016; 12(3):217-20. PubMed ID: 27435442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Should high-dose buprenorphine be withdrawn from the French market?].
    Rolland B; Muyssen A; Danel T; Cottencin O
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
    [No Abstract]   [Full Text] [Related]  

  • 60. Fulfilling a Need: A Residency-Based Program to Preserve a Suboxone Treatment Program in a Rural Community.
    Buck MC; McCormick AN; Meagher MM; Kauppila G; Witt TJ
    Ann Fam Med; 2021; 19(6):561. PubMed ID: 34750133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.